Vaccinex (Vaccinex) Dividend Payout Ratio : 0.00 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Vaccinex Dividend Payout Ratio?

Vaccinex's dividend payout ratio for the months ended in Mar. 2024 was 0.00.

The historical rank and industry rank for Vaccinex's Dividend Payout Ratio or its related term are showing as below:

VCNX's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.44
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-06-06), the Dividend Yield % of Vaccinex is 0.00%.

Vaccinex's Dividends per Share for the months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Vaccinex Dividend Payout Ratio Historical Data

The historical data trend for Vaccinex's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaccinex Dividend Payout Ratio Chart

Vaccinex Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

Vaccinex Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Vaccinex's Dividend Payout Ratio

For the Biotechnology subindustry, Vaccinex's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaccinex's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaccinex's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Vaccinex's Dividend Payout Ratio falls into.

Vaccinex Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Vaccinex's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-47.396
	=	N/A

Vaccinex's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-3.849
	=	N/A

Vaccinex (NAS:VCNX) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Vaccinex Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Vaccinex's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaccinex (Vaccinex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaccinex Inc (NAS:VCNX) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

1895 Mount Hope Avenue, Rochester, NY, USA, 14620

Website

https://www.vaccinex.com

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements.

Executives

Van Strydonck, Gerald E.	director	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Maurice Zauderer	director, 10 percent owner, officer: President and CEO	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Albert Friedberg	director, 10 percent owner
Jacob B. Frieberg	director	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Elizabeth E. Evans	officer: Chief Operating Officer	C/O VACCINEX, INC., 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Robert Scala	officer: Chief Commercial Officer	1895 MT HOPE AVENUE, ROCHESTER NY 14620
Chrystyna Bedrij Stecyk	director	1895 MT. HOPE AVENUE, ROCHESTER NY 14620
Vaccinex, Inc.	director	1895 MOUNT HOPE AVE, ROCHESTER NY 14620
Jeff Goater	director	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Bala S Manian	director	1025 TERRA BELLA AVE, MOUNTAIN VIEW CA 94043
Barbara Yanni	director	1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Alejandro M. Berlin	director	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
John E. Leonard	officer: SVP, Development	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Ernest S. Smith	officer: SVP, Research & CSO	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Raymond E. Watkins	officer: SVP & Chief Operating Officer	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620